Registered title, quoted from ClinicalTrials.gov
Neoadjuvant Iparomlimab and Tuvonralimab With Nab-P-SOX in Locally Advanced Gastric or Gastroesophageal Junction Cancer
An open trial on stomach cancer, registered on ClinicalTrials.gov. Led by Ruijin Hospital; 0 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07867392, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 5
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (5 points)Hide the checklist
18 years to 75 years; sex: all
Registered eligibility fields
Histologically confirmed gastric or gastroesophageal junction adenocarcinoma, clinical stage cT3-4aN+M0
Inclusion criterion 2
Within 12 months: myocardial infarction, unstable angina, or NYHA class III/IV heart failure
Exclusion criterion 12
ECOG performance status 0-1
Inclusion criterion 6
Active HIV, HBV, or HCV infection
Exclusion criterion 16
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: earlier treatment; blood tests: counts, liver and kidney function; scans and measurable lesions; pregnancy, breastfeeding and contraception.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07867392, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Age 18-75 years
- Histologically confirmed gastric or gastroesophageal junction adenocarcinoma, clinical stage cT3-4aN+M0
- Resectable disease, as determined by the surgical investigator
- No prior radiotherapy, chemotherapy, or other systemic antitumor therapy
- HER-2 negative
- ECOG performance status 0-1
- Life expectancy greater than 6 months
- Adequate organ function: hemoglobin >= 90 g/L; absolute neutrophil count >= 1.5 x 10\^9/L; platelet count >= 100 x 10\^9/L; serum creatinine <= 1.5 x ULN; ALT/AST <= 2.5 x ULN; total bilirubin <= 1.5 x ULN; amylase/lipase < 1.5 x ULN; INR/APTT <= 1.5 x ULN; urine protein < 2+; LVEF >= 50%
- Women of childbearing potential must be non-pregnant, non-lactating, and agree to use adequate contraception
- Provision of written informed consent and anticipated good compliance
Exclusion Criteria:
- Known allergy or hypersensitivity to the investigational drug(s) or excipients
- History of other prior antitumor therapy
- Therapeutic full-dose anticoagulation or thrombolysis within 10 days prior to first dose
- Requirement for systemic corticosteroids or immunosuppressive therapy within 2 weeks prior to first dose
- Active autoimmune disease or autoimmune disease with high risk of relapse
- Within 6 months: gastrointestinal perforation, fistula, or obstruction; Crohn's disease or ulcerative colitis; or extensive intestinal resection
- Symptomatic and uncontrolled brain or leptomeningeal metastases
- History of interstitial lung disease/pneumonitis or pulmonary hypertension
- History of organ transplantation
- Uncontrolled hypertension (>150/100 mmHg), diabetes mellitus, or cardiac arrhythmia
- Arterial or venous thrombotic/embolic event within 6 months
- Within 12 months: myocardial infarction, unstable angina, or NYHA class III/IV heart failure
- Drainage of ascites, pleural effusion, or pericardial effusion within 4 weeks prior to enrollment
- Non-healing wound, active ulcer, or untreated fracture
- Other active malignancy
- Active HIV, HBV, or HCV infection
- Major surgery within 4 weeks prior to first dose
- Any condition that, in the investigator's judgment renders the patient unsuitable for study participation
Quoted from ClinicalTrials.gov, NCT07867392, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07867392, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.